Dapagliflozin, Advanced Chronic Kidney Disease, and Mortality Dapagliflozin, Advanced Chronic Kidney Disease, and Mortality
A report on the effects of the SGLT2 inhibitor dapagliflozin on morbidity and mortality in patients with chronic kidney disease suggests these drugs have potential beyond their original use in T2DM.European Heart Journal (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - April 28, 2021 Category: Intensive Care Tags: Nephrology Journal Article Source Type: news
Women, Black, Asian Patients Least Likely to Get SGLT2 Inhibitors Women, Black, Asian Patients Least Likely to Get SGLT2 Inhibitors
"If left unaddressed, these inequities in [SGLT2 Inhibitor] utilization will continue to widen well-documented disparities in cardiovascular and kidney outcomes in the [United States]."Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - April 23, 2021 Category: Cardiology Tags: Diabetes & Endocrinology News Source Type: news
Why Choose Between SGLT2 Inhibitors and GLP1-RA? Why Choose Between SGLT2 Inhibitors and GLP1-RA?
In this commentary, the author urges clinicians to stop wasting time debating whether to use GLP-1RA or an SGLT2 inhibitor in a given patient with T2DM: just pick one--or possibly even both.Circulation (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 20, 2021 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news
Gender, Race Affects Access to SGLT2-Inhibitor Therapy for T2DM
MONDAY, April 16, 2021 -- There are racial/ethnic, gender, and socioeconomic disparities apparent in access to sodium-glucose cotransporter 2 (SGLT2) inhibitor treatment for patients with diabetes, according to a study published online April 15 in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 19, 2021 Category: Pharmaceuticals Source Type: news
GLP-1 Agonists and SGLT2 Inhibitors in HF Treatment GLP-1 Agonists and SGLT2 Inhibitors in HF Treatment
Although study results have been postive, particularly for SGLT2 inhibitors, questions still need to be answered about how these agents fit into treatment for heart failure.American College of Cardiology & Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - April 14, 2021 Category: Cardiology Tags: Cardiology Commentary Source Type: news
SGLT2 Inhibitors in T1D:'People Are Using Them Now'SGLT2 Inhibitors in T1D:'People Are Using Them Now '
Dr Anne Peters talks about what you need to know regarding off-label use of SGLT2 inhibitors in type 1 diabetes.Medscape Diabetes & Endocrinology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 30, 2021 Category: Consumer Health News Tags: Diabetes & Endocrinology Commentary Source Type: news
Mar 19 2021 This Week in Cardiology Mar 19 2021 This Week in Cardiology
COVID-19, Fish Oil and AF risk, SGLT2 inhibitors and renal outcomes, and TAVR vs SAVR are the topics discussed by John Mandrola, MD, in this week ’s podcast.theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - March 19, 2021 Category: Cardiology Tags: Cardiology Commentary Source Type: news
Ertugliflozin: Renal Benefits in Additional VERTIS CV Analyses Ertugliflozin: Renal Benefits in Additional VERTIS CV Analyses
The main composite renal endpoint from VERTIS CV didn ' t show significant benefit from ertugliflozin over placebo, but in additional analyses showed kidney benefits from this SGLT2 inhibitor.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - March 18, 2021 Category: Cardiology Tags: Diabetes & Endocrinology News Source Type: news
La FDA actualiza las etiquetas de los inhibidores del SGLT2 para la diabetes a fin de incluir advertencias sobre concentraciones de ácido demasiado altas en la sangre e infecciones graves del tracto urinario
[04/12/2015] Una reciente evaluaci ón de seguridad realizada por la Administración de Alimentos y Medicamentos de los Estados Unidos (FDA, por sus siglas en inglés) ha llevado a la adición de advertencias a las etiquetas de una clase específica de medicamentos para la diabetes de tipo 2, llamados inhibidores del cotransportador de sodio-glucosa tipo 2 (SGLT2, por sus siglas en inglés), sobre el riesgo de presentar concentraciones de ácido demasiado elevadas en la sangre e infecciones graves del tracto urinario. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - February 26, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Further Warning on SGLT2 Inhibitor Use and DKA Risk in COVID-19 Further Warning on SGLT2 Inhibitor Use and DKA Risk in COVID-19
A cluster of cases of diabetic ketoacidosis in which there was no hyperglycemia supports recommendations that SGLT2 inhibitors be discontinued in patients with type 2 diabetes who become ill with COVID-19.Medscape Medical News (Source: Medscape Emergency Medicine Headlines)
Source: Medscape Emergency Medicine Headlines - January 18, 2021 Category: Emergency Medicine Tags: Infectious Diseases News Source Type: news
Jan 15 2021 This Week in Cardiology Jan 15 2021 This Week in Cardiology
COVID, ACE/ARBs, left atrial appendage closure, SGLT2 inhibitors, and a clue in AF mechanisms are the topics discussed by John Mandrola, MD, in this week ’s podcast.theheart.org on Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 15, 2021 Category: Consumer Health News Tags: Cardiology Commentary Source Type: news
Jan 15 2021 This Week in Cardiology Jan 15 2021 This Week in Cardiology
COVID, ACE/ARBs, left atrial appendage closure, SGLT2 inhibitors, and a clue in AF mechanisms are the topics discussed by John Mandrola, MD, in this week ’s podcast.theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - January 15, 2021 Category: Cardiology Tags: Cardiology Commentary Source Type: news
Biomarker HF Risk Score in Diabetes Seen as SGLT2i Lodestar Biomarker HF Risk Score in Diabetes Seen as SGLT2i Lodestar
Together, 4 ' easily measured ' biomarkers predicted 5-year heart failure risk in patients with diabetes or prediabetes, potentially identifying best candidates for SGLT2 inhibitor therapy, some say.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - January 14, 2021 Category: Cardiology Tags: Cardiology News Source Type: news
Euglycemic DKA ID ’ d in T2DM Patients With COVID - 19
Five cases of euDKA identified in patients with type 2 diabetes using SGLT2 inhibitors who developed SARS - CoV - 2 infection (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - January 5, 2021 Category: Respiratory Medicine Tags: Endocrinology, Family Medicine, Infections, Internal Medicine, Critical Care, Emergency Medicine, Nephrology, Nursing, Pharmacy, Pulmonology, Journal, Source Type: news
Top Cardiology Trials of 2020 in Review Top Cardiology Trials of 2020 in Review
The annual tradition continues as did cardiology research despite a pandemic. Trials on fish oils, statins, SGLT2 inhibitors, and antiplatelets are among the selections of Drs Harrington and Gibson.theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - December 15, 2020 Category: Cardiology Tags: Cardiology Expert Interview Source Type: news
